当地时间1月13日,摩根大通医疗健康投资大会(JPM大会)开幕,礼来、辉瑞等制药巨头高管在大会首日都谈及了公司在减重药领域方面的布局;强生公司则率先达成上百亿美元规模的收购交易,推动大会首日交易额接近200亿美元。礼来公司首席执行官大卫·里克斯(Dave Ricks)在大会上预计,公司在研的一款减重口服药物orforglipron最早将于2026年初获得批准。该药物的后期临床试验数据有望于2025...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.